• Criptomonedas
  • Mercados de Predicción
  • Noticias
  • Trading Agéntico
  • Artículos
  • Ligas

Buscar Criptomonedas

Criptomonedas de tendencia

CoinRithm

Empresa

Entidad legal
Bees-x Limited
Número de empresa
13308136
Constituida en
England and Wales
Domicilio social
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm es un servicio de información e investigación operado por Bees-x Limited. No está autorizado por la Financial Conduct Authority (FCA) para realizar actividades reguladas, y nada en este sitio constituye asesoramiento financiero.

Explorar

CriptomonedasMercados de PredicciónNoticiasArtículosAgent ArenaLigas

Funciones

TableroComercio SimuladoTrading AgénticoPortafolioLista de SeguimientoConfiguraciones

Empresa

Sobre NosotrosMetodologiaTérminos de UsoPolítica de PrivacidadPolítica de CookiesDescargo de Responsabilidad

Soporte

Contacto SoporteFAQKit para desarrolladoresDocumentación MCP

Sociales

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Reservados todos los derechos.
Disponible en Google PlayDescargar en App Store
  • Inicio
  • MercadosMercados de Predicción
  • Noticias
  • Tablero
  1. Mercados de Predicción
  2. Health & Medicine
  3. When will the FDA reclassify BPC-157 to Category 1?
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

4.0% (24h)Health & MedicineOne-Off19d
KalshiKalshiComprobar disponibilidadKYC requerido2% de comisión
Probabilidad implícita actual
Before July
Before July 5%+4.0%
Líder entre 6 opciones
Calidad del mercado

28 / 100

Baja calidad
Volumen 24h

0,1 €

Liquidez

103,8 €

Baja liquidez
Compra / Venta

1.0% / 6.0%

Spread

500.0%

Spread amplio
Datos de mercado

Actualizado hace 2 minutos

24 mar 26, 14:001 jul 26, 3:59

Tendencias

Resultado24hProbabilidad

Resultado elegido

Before July5%

Reglas

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sí: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sí: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sí: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Activos en estos temas

BitcoinBTC$62,871.62+2.52%EthereumETH$1,658.53+1.90%SolanaSOL$65.29+1.89%DogecoinDOGE$0.085+1.76%XRPXRP$1.12+0.73%BNBBNB$596.99+1.87%

Noticias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Reglas

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.